Cargando…

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience

There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kabut, Tomáš, Weinbergerová, Barbora, Folber, František, Lengerová, Martina, Mayer, Jiří
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622319/ https://www.ncbi.nlm.nih.gov/pubmed/37612466 http://dx.doi.org/10.1038/s41409-023-02081-6

Ejemplares similares

Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use
por: Kovacsova, Flora, et al.
Publicado: (2023)

Bronchoalveolar lavage fluid and serum 1,3-β-d-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance
por: Weinbergerova, Barbora, et al.
Publicado: (2020)

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
por: Weinbergerová, Barbora, et al.
Publicado: (2023)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
por: Jaskula, Emilia, et al.
Publicado: (2012)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Whole CMV Proteome Pattern Recognition Analysis after HSCT Identifies Unique Epitope Targets Associated with the CMV Status
por: Pérez-Bercoff, Lena, et al.
Publicado: (2014)

The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder
por: Szmit, Zofia, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

"Aciclovir en el Tratamiento de la Varicela" /
por: García Domínguez, Juan Manuel
Publicado: (1995)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
por: Morris, Emma C., et al.
Publicado: (2019)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Aciclovir/elasomeran: Encephalitis and acute renal insufficiency: case report
Publicado: (2022)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Furuno, Jon P, et al.
Publicado: (2017)

1747. Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients
por: Watts, Corey, et al.
Publicado: (2019)

Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
por: Widmann, Thomas, et al.
Publicado: (2008)

Aciclovir: Acute kidney injury because of intratubular precipitation of crystals: case report
Publicado: (2022)

Aciclovir/immunosuppressants: West-Nile-virus-infections and graft failure: case report
Publicado: (2021)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

Allogeneic HSCT for Symptomatic Female X-linked Chronic Granulomatous Disease Carriers
por: Tsilifis, Christo, et al.
Publicado: (2023)

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review
por: Sonneveld, Nicole, et al.
Publicado: (2023)

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Use of CRRT-CVVH in a hemato-oncological ICU in patients treated with defibrotide for veno-occlusive disease in patients after allogeneic hematopoetic stem cell transplantation: single-center experience
por: Navratil, M, et al.
Publicado: (2010)

Aciclovir/dexamethasone/remdesivir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
por: Zhang, Rui, et al.
Publicado: (2021)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain
por: Zhang, Shannon, et al.
Publicado: (2019)

Clinical significance of T cell receptor excision circle (TREC) quantitation after allogenic HSCT
por: Mikhael, Neveen Lewis, et al.
Publicado: (2019)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Reekie, Joanne, et al.
Publicado: (2020)

2704. Real-world safety and effectiveness of letermovir for preventing cytomegalovirus (CMV) disease in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT): Final results of post-marketing surveillance (PMS) in Japan
por: Fukuda, Masaki, et al.
Publicado: (2023)

Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility
por: Brunnemann, Anne-Kathrin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sfn1a3e03e9ddpt1q1ipmcauvq